pre-IPO PHARMA
COMPANIES
VC
JOBS
NEWS
CONTACT
Close ×
COMPANIES
VC
JOBS
NEWS
CONTACT
nikang-therapeutics PRESS RELEASE ARCHIVE
Jan 18, 2023
NiKang Therapeutics Appoints Anne E. Borgman, M.D., to Board of Directors
May 3, 2022
NiKang Therapeutics and Hansoh Pharma Announce Strategic Collaboration and License Agreement for NKT2152 in Greater China
Apr 8, 2022
NiKang Therapeutics Presents Preclinical Data Highlighting NKT2152’s Therapeutic Potential in Clear Cell Renal Cell Carcinoma (ccRCC) and Solid Tumors Beyond ccRCC at AACR Annual Meeting 2022
Jan 5, 2022
NiKang Therapeutics and AVEO Oncology Announce a Clinical Trial Collaboration and Supply Agreement to Evaluate the Combination of NKT2152, a HIF2α Inhibitor, and FOTIVDA (tivozanib) for the Treatment of Advanced Clear Cell Renal Cell Carcinoma
Nov 30, 2021
NiKang Therapeutics and Pfizer Enter Clinical Trial Collaboration and Supply Agreement to Evaluate Novel Combination Therapies for the Treatment of Advanced Clear Cell Renal Cell Carcinoma
Nov 15, 2021
NiKang Therapeutics Announces First Patient Dosed in A Phase 1/2 Study Evaluating NKT2152, a Small Molecule that Inhibits Hypoxia Inducible Factor 2α (HIF2α), for the Treatment of Advanced Clear Cell Renal Cell Carcinoma
Jun 10, 2021
NiKang Therapeutics Appoints Robert Xin, M.D., Ph.D., as Chief Medical Officer
May 26, 2021
NiKang Therapeutics Announces Completion of $200 Million Series C Financing to Advance Highly Differentiated Small Molecules Addressing Difficult-to-Drug Targets
Apr 23, 2020
Hansoh Pharma and NiKang Therapeutics Enter into a Development and Commercialization Partnership for a Novel Treatment for Anti-Viral Diseases in China
